Close Menu

NEW YORK – NeoGenomics announced Thursday the pricing of its proposed offerings of shares of common stock and convertible senior notes.

The company is offering 4.4 million shares of its common stock at $28.50 per share, with expected gross proceeds of $125.4 million, and $175 million of its 1.25 percent convertible senior notes due in 2025. The senior notes will mature on May 1, 2025. 

NeoGenomics also granted the underwriters of the offerings a 30-day option to buy an additional 666,000 shares of common stock at the public offering price and $26.25 million of senior notes.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.

Noel Rose, the "father of autoimmunity," has died at 92, the Washington Post reports.

According to CNN, Legionella was discovered in buildings leased by the Centers for Disease Control and Prevention as they reopened following coronavirus pandemic-related closures.

In PLOS this week: genetic analysis of malaria parasite populations in Southeast Asia, genomic surveillance of yellow fever virus in São Paulo, and more.